MITO END-3: A randomized phase II trial of avelumab plus carboplatin and paclitaxel compared to carboplatin and paclitaxel in advanced or recurrent endometrial cancer.
MITO END-3: A randomized phase II trial of avelumab plus carboplatin and paclitaxel compared to carboplatin and paclitaxel in advanced or recurrent endometrial cancer.
Adding checkpoint inhibitors to first-line chemotherapy might improve the outcome of advanced/recurrent endometrial cancer (EC) patients. MITO END3 is a randomized phase II trial comparing avelumab plus carboplatin/paclitaxel versus carboplatin/paclitaxel in patients with advanced/recurrent EC and ECOG performance status 0-1. Primary endpoint was progression-free survival (PFS); superiority of the experimental arm was tested with 80% power and one-tailed alpha 0·20; subgroup analyses according to mismatch repair (MMR) status were planned. ClinicalTrials.gov NCT03503786.
This study was partially funded, and avelumab was supplied, by Pfizer as part of an alliance between Pfizer and Merck (CrossRef Funder ID: 10.13039/100009945).
- AZIENDA SANITARIA UNIVERSITARIA FRIULI CENTRALE Italy
- Ospedale "Santa Maria delle Croci" di Ravenna Italy
- Ospedale San Martino Italy
- FON University Former Yugoslav Republic of Macedonia
- Centro di Riferimento Oncologico Italy
endometrial cancer; first line; Chemotherapy; Avelumab
endometrial cancer; first line; Chemotherapy; Avelumab
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!